Walvax Biotechnology Co Ltd
SZSE:300142
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.9
24.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Walvax Biotechnology Co Ltd
Accounts Receivables
Walvax Biotechnology Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
W
|
Walvax Biotechnology Co Ltd
SZSE:300142
|
Accounts Receivables
¥3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
43%
|
CAGR 10-Years
17%
|
|
|
Beigene Ltd
HKEX:6160
|
Accounts Receivables
¥2.5B
|
CAGR 3-Years
86%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accounts Receivables
¥271m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accounts Receivables
¥3B
|
CAGR 3-Years
63%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accounts Receivables
¥949.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
3%
|
CAGR 10-Years
25%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accounts Receivables
¥25.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
42%
|
CAGR 10-Years
50%
|
|
Walvax Biotechnology Co Ltd
Glance View
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.
See Also
What is Walvax Biotechnology Co Ltd's Accounts Receivables?
Accounts Receivables
3B
CNY
Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Accounts Receivables amounts to 3B CNY.
What is Walvax Biotechnology Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%
Over the last year, the Accounts Receivables growth was -19%. The average annual Accounts Receivables growth rates for Walvax Biotechnology Co Ltd have been 9% over the past three years , 43% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
